ArticleNature nanotechnology2018
Pre-adsorption of antibodies enables targeting of nanocarriers despite a biomolecular corona.
Article in Nature nanotechnology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
99 citing papers in PubMed.
- Comprehensive overview of AI methodologies in nano-drug delivery Optimization and Design.NPJ precision oncology · 2026Review
- Gold Nanoparticles in Prostate Cancer: Advances in Targeted Therapy, Diagnostics, and Precision Nanomedicine.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Turning Unpredictable Biomolecule Adsorption to Controlled Corona Formation: Focus on Carbon Nanomaterials.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Integrated top-down and bottom-up proteomics enables precise characterization of proteoforms within the protein corona.Nature communications · 2026Article
- The protein corona at the nano-bio interface: the need for standardized methodology and opportunities for neurodegenerative disease intervention.RSC advances · 2026Review
- Article
- Enhancing the targeting ability of metal-organic frameworks in cancer therapy and diagnosis.Nature reviews. Chemistry · 2026Review
- cDC1 Subtype-Specific In Vivo Targeting of Liposomes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Smart Nanoformulations for Oncology: A Review on Overcoming Biological Barriers with Active Targeting, Stimuli-Responsive, and Controlled Release for Effective Drug Delivery.Pharmaceutics · 2026Review
- Recent advances in cancer nanomedicine: From smart targeting to personalized therapeutics - pioneering a new era in precision oncology.Materials today. Bio · 2026Review
- Integrated top-down and bottom-up mass spectrometry enables precise characterization of proteoforms and their post-translational modifications within the protein corona.Research square · 2025Article
- Therapeutic Implications of Biomolecular Corona on Lipid Nanoparticle-Based Gene Delivery Systems.Small science · 2025Article
- Advancing engineering design strategies for targeted cancer nanomedicine.Nature reviews. Cancer · 2025Review
- Galloylated liposomes enable targeted drug delivery by overcoming protein corona shielding.Nature communications · 2025Article
- Protein Adsorption on Nano- and Microparticles: Dependence on Morphological and Physicochemical Properties of Particles and Effect on Particle-Cell Interactions.Nanomaterials (Basel, Switzerland) · 2025Review
- TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives.Molecular biomedicine · 2025Review
- Layer-by-layer coating strategy to functionalize the magnetic nanoparticles for their multi-functionalization.Discover nano · 2025Article
- Balancing stealth and targeting to improve nanomedicine efficacy.Nature nanotechnology · 2025Article
- Article
- Multifunctional Nanomaterials: Recent Advancements in Cancer Therapeutics and Vaccines.Indian journal of microbiology · 2025Article
39 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To promote drug delivery to exact sites and cell types, the surface of nanocarriers is functionalized with targeting antibodies or ligands, typically coupled by covalent chemistry. Once the nanocarrier is exposed to biological fluid such as plasma, however, its surface is inevitably covered with various biomolecules forming the protein corona, which masks the targeting ability of the nanoparticle. Here, we show that we can use a pre-adsorption process to attach targeting antibodies to the surface of the nanocarrier. Pre-adsorbed antibodies remain functional and are not completely exchanged or covered by the biomolecular corona, whereas coupled antibodies are more affected by this shielding. We conclude that pre-adsorption is potentially a versatile, efficient and rapid method of attaching targeting moieties to the surface of nanocarriers.
Indexed as
Identifiers
29915272What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.